Qiagen QGEN

NYSE QGEN

$44.42 -0.59 (-1.31%)

As of: Sep 29, 2026 · 3:59 PM EDT

Key Stats

Market Cap9.76 Bn

P/E23.88

P/S4.65

Div. Yield5.87

Total Debt (Qtr)1.64 Bn

Revenue Growth (1y) (Qtr)0.28

Add ratio to table…

About

QIAGEN N. V. is a leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. The company isolates and processes DNA, RNA and proteins from blood, tissue and other materials using its sample technologies, prepares biomolecules for analysis with assay technologies, interprets data through bioinformatics software and knowledge bases, and integrates these processes into seamless workflows via automation solutions. QIAGEN serves over 500,000 customers globally in Life Sciences and molecular diagnostics for clinical healthcare, employing approximately 5,700 people across more than 35 locations worldwide as of December 31, 2025.

QIAGEN generates revenue through the sale of consumables and related revenues, as well as instruments and related services. Consumables include sample and assay kits, reagents, and other disposable products used in molecular testing workflows, while instruments and related services encompass sequencing platforms, PCR systems, automation equipment, and maintenance, training, and technical support offerings. The company's revenue is derived from a diverse customer base spanning academic research institutions, pharmaceutical and biotechnology companies, applied testing laboratories, forensic facilities, and clinical healthcare providers engaged in molecular diagnostics.

The company operates through the following segments: Sample Technologies, Assay Technologies, and Bioinformatics and Digital Solutions.

Sample Technologies: This segment focuses on the development and commercialization of products that isolate and purify nucleic acids and proteins from biological samples. Key product lines include QIAamp, QIAcube, and MagAttract systems, which are widely used for DNA and RNA extraction in research and clinical settings. The segment also includes the QuantiFERON technology platform, best known for its use in detecting latent tuberculosis infection through interferon-gamma release assays.
Assay Technologies: This segment prepares biomolecules for downstream analysis through polymerase chain reaction (PCR), real-time PCR, and other amplification and detection technologies. Core offerings include the QIAstat-Dx syndromic testing platform for rapid infectious disease diagnosis, the QIAcuity digital PCR system for absolute quantification of nucleic acids, and various kits for genotyping, mutation analysis, and pathogen detection. These products are designed to deliver high sensitivity, specificity, and reproducibility in both research and diagnostic applications.
Bioinformatics and Digital Solutions: This segment provides software, knowledge bases, and analytical tools that interpret complex genomic and molecular data to generate actionable insights. The QIAGEN Digital Insights portfolio includes platforms such as CLC Bio, Ingenuity Pathway Analysis, and OmicSoft, which support variant interpretation, multi-omics integration, and biomedical research workflows. These digital solutions are increasingly integrated with instrument and consumable offerings to create end-to-end Sample to Insight workflows for customers in precision oncology, infectious disease, and genetic disease research.

QIAGEN holds a leading position in the global life science and molecular diagnostics industry, competing with companies such as Thermo Fisher Scientific, Danaher Corporation, and Roche Holding AG. The company's competitive advantages stem from its integrated Sample to Insight approach, strong intellectual property portfolio, extensive global distribution network, and deep expertise in sample preparation and assay development. Its focus on high-growth areas such as digital PCR, syndromic testing, and bioinformatics enables differentiation in markets where workflow efficiency and data interpretation are critical to customer success.

QIAGEN serves more than 500,000 customers across the globe, including academic and government research laboratories, pharmaceutical and biotechnology firms engaged in drug discovery and development, clinical diagnostic laboratories performing infectious disease and genetic testing, forensic laboratories involved in human identification and criminal investigations, and applied testing facilities in food safety, environmental monitoring, and industrial quality control. The company's broad customer access is supported by direct sales operations in over 40 countries and partnerships with third-party distributors to reach additional markets worldwide.

Investment Thesis

▲ Bull case

Qiagen N.V. is positioned to capture significant untapped market potential in the latent tuberculosis testing space, with only 40% of the estimated 75 million annual global tests converted from skin tests to modern IGRA-based methods like QuantiFERON, leaving a substantial runway for growth. The company’s leadership in this niche is reinforced by its unique CD4/CD8 antigen technology, which provides superior sensitivity and specificity in immunocompromised patients—a growing demographic due to rising rates of HIV, hepatitis, and biologic therapies—creating a defensible moat that competitors cannot easily replicate. This technological edge, combined with the ongoing global shift away from tuberculin skin tests (TSTs) due to their false-positive issues in BCG-vaccinated populations and logistical burdens (requiring two visits), supports a structural expansion of the addressable market beyond current estimates, particularly in high-burden regions where public health initiatives are increasingly adopting IGRA standards.
The recently launched CLIA 2 chemistry, developed in partnership with DiaSorin, delivers a 25% faster turnaround time and enables labs to process up to 75% more patients per hour, directly addressing laboratory pain points around throughput and operational efficiency. This innovation is not merely incremental; it represents a critical inflection point in adoption velocity, especially in high-volume settings like centralized reference labs and public health programs, where faster results reduce patient loss to follow-up and improve workflow economics. Early feedback from European and U.S. customers post-FDA approval in February 2026 indicates strong traction, with conversion plans progressing on schedule and no reported dissatisfaction, suggesting that the transition from legacy chemistries is smoother than anticipated and could accelerate market share gains beyond the current 40% conversion rate.
Qiagen N.V.’s strategic pivot toward a full sample-to-insight ecosystem—encompassing end-to-end automation via the Inpeco partnership (targeting late 2027 launch), AI-driven risk stratification using 13 million de-identified longitudinal patient records, and seamless LIAISON integration—creates multiple layered growth engines that are underappreciated by the market. The AI tool, in particular, transforms QuantiFERON from a diagnostic test into a predictive clinical decision-support platform capable of identifying high-risk latent TB patients most likely to progress to active disease, thereby increasing treatment adherence, reducing long-term healthcare costs, and opening new reimbursement pathways. This vertical integration, built on two decades of proprietary data and deep partnerships with DiaSorin and Inpeco, establishes a defensible platform that competitors lack the data, expertise, or ecosystem to replicate, positioning Qiagen N.V. to command premium pricing and expand into adjacent markets like diabetes and dialysis-related TB screening.

Qiagen N.V. is positioned to capture significant untapped market potential in the latent tuberculosis testing space, with only 40% of the estimated 75 million annual global tests converted from skin tests to modern IGRA-based methods like QuantiFERON, leaving a substantial runway for growth. The company’s leadership in this niche is reinforced by its unique CD4/CD8 antigen technology, which provides superior sensitivity and specificity in immunocompromised patients—a growing demographic due to rising rates of HIV, hepatitis, and biologic therapies—creating a defensible moat that competitors cannot easily replicate. This technological edge, combined with the ongoing global shift away from tuberculin skin tests (TSTs) due to their false-positive issues in BCG-vaccinated populations and logistical burdens (requiring two visits), supports a structural expansion of the addressable market beyond current estimates, particularly in high-burden regions where public health initiatives are increasingly adopting IGRA standards.
The recently launched CLIA 2 chemistry, developed in partnership with DiaSorin, delivers a 25% faster turnaround time and enables labs to process up to 75% more patients per hour, directly addressing laboratory pain points around throughput and operational efficiency. This innovation is not merely incremental; it represents a critical inflection point in adoption velocity, especially in high-volume settings like centralized reference labs and public health programs, where faster results reduce patient loss to follow-up and improve workflow economics. Early feedback from European and U.S. customers post-FDA approval in February 2026 indicates strong traction, with conversion plans progressing on schedule and no reported dissatisfaction, suggesting that the transition from legacy chemistries is smoother than anticipated and could accelerate market share gains beyond the current 40% conversion rate.
Qiagen N.V.’s strategic pivot toward a full sample-to-insight ecosystem—encompassing end-to-end automation via the Inpeco partnership (targeting late 2027 launch), AI-driven risk stratification using 13 million de-identified longitudinal patient records, and seamless LIAISON integration—creates multiple layered growth engines that are underappreciated by the market. The AI tool, in particular, transforms QuantiFERON from a diagnostic test into a predictive clinical decision-support platform capable of identifying high-risk latent TB patients most likely to progress to active disease, thereby increasing treatment adherence, reducing long-term healthcare costs, and opening new reimbursement pathways. This vertical integration, built on two decades of proprietary data and deep partnerships with DiaSorin and Inpeco, establishes a defensible platform that competitors lack the data, expertise, or ecosystem to replicate, positioning Qiagen N.V. to command premium pricing and expand into adjacent markets like diabetes and dialysis-related TB screening.

▼ Bear case

Qiagen N.V.’s reliance on the latent tuberculosis testing market exposes it to significant concentration risk, as the core QuantiFERON business remains heavily dependent on public health funding and immigration screening programs—particularly in the U.S.—which have shown volatility due to shifting policy priorities and budget constraints. Management acknowledged a $30–35 million revenue impact from losses in the U.S. immigrant market and certain Middle Eastern countries, a figure that represents a material portion of the QuantiFERON franchise and suggests that growth in other segments (e.g., immunocompromised patients, healthcare workers) may not be sufficient to offset these declines, especially if global TB control funding faces further retrenchment amid competing health priorities.
The anticipated benefits from the Inpeco-driven end-to-end automation platform, while technologically impressive, face substantial execution risk due to its late 2027 launch timeline, which leaves the company vulnerable to competitive encroachment in the near term. Although Qiagen N.V. claims uniqueness in offering full automation for IGRA-based TB testing, the prolonged development cycle increases the likelihood that alternative solutions—such as modular automation from existing partners like Tecan and the company’s own flexible workflow options—could satisfy customer needs without waiting for the Inpeco system, thereby diminishing the perceived urgency and value proposition of the upcoming launch. Furthermore, the automation solution is purpose-built exclusively for QuantiFERON, limiting its applicability to other assays and reducing its potential to drive broader platform adoption beyond the core TB franchise.
The AI-enabled risk stratification tool, despite being touted as a differentiator based on 13 million longitudinal patient records, remains unproven in clinical utility and faces significant hurdles to adoption, including unclear reimbursement models, integration challenges with electronic health records, and skepticism from clinicians who may view it as an incremental add-on rather than a necessity. Management’s cautious approach to engaging with organizations like WHO and Stop TB—preferring to wait for “better data” before formal discussions—suggests internal uncertainty about the tool’s real-world impact, and the 2027 launch target aligns with the automation platform, creating a concentration of execution risk in the same timeframe. Without clear evidence that the tool improves patient outcomes or reduces costs at scale, its ability to drive premium pricing or market expansion remains speculative, and the investment in AI may not yield proportional returns if adoption lags or if competitors develop simpler, cheaper risk-assessment methods using more accessible data.

Qiagen N.V.’s reliance on the latent tuberculosis testing market exposes it to significant concentration risk, as the core QuantiFERON business remains heavily dependent on public health funding and immigration screening programs—particularly in the U.S.—which have shown volatility due to shifting policy priorities and budget constraints. Management acknowledged a $30–35 million revenue impact from losses in the U.S. immigrant market and certain Middle Eastern countries, a figure that represents a material portion of the QuantiFERON franchise and suggests that growth in other segments (e.g., immunocompromised patients, healthcare workers) may not be sufficient to offset these declines, especially if global TB control funding faces further retrenchment amid competing health priorities.
The anticipated benefits from the Inpeco-driven end-to-end automation platform, while technologically impressive, face substantial execution risk due to its late 2027 launch timeline, which leaves the company vulnerable to competitive encroachment in the near term. Although Qiagen N.V. claims uniqueness in offering full automation for IGRA-based TB testing, the prolonged development cycle increases the likelihood that alternative solutions—such as modular automation from existing partners like Tecan and the company’s own flexible workflow options—could satisfy customer needs without waiting for the Inpeco system, thereby diminishing the perceived urgency and value proposition of the upcoming launch. Furthermore, the automation solution is purpose-built exclusively for QuantiFERON, limiting its applicability to other assays and reducing its potential to drive broader platform adoption beyond the core TB franchise.
The AI-enabled risk stratification tool, despite being touted as a differentiator based on 13 million longitudinal patient records, remains unproven in clinical utility and faces significant hurdles to adoption, including unclear reimbursement models, integration challenges with electronic health records, and skepticism from clinicians who may view it as an incremental add-on rather than a necessity. Management’s cautious approach to engaging with organizations like WHO and Stop TB—preferring to wait for “better data” before formal discussions—suggests internal uncertainty about the tool’s real-world impact, and the 2027 launch target aligns with the automation platform, creating a concentration of execution risk in the same timeframe. Without clear evidence that the tool improves patient outcomes or reduces costs at scale, its ability to drive premium pricing or market expansion remains speculative, and the investment in AI may not yield proportional returns if adoption lags or if competitors develop simpler, cheaper risk-assessment methods using more accessible data.

Geographical Breakdown of Revenue (2025)

Peer group

Peer Comparison

Companies in the Life Sciences Tools

View all peers

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	TMO	Thermo Fisher Scientific Inc.	250.84 Bn	36.13	5.41	42.55 Bn
2	ABT	Abbott Laboratories	174.73 Bn	32.40	3.75	32.61 Bn
3	DHR	Danaher Corp /De/	159.85 Bn	40.06	6.37	26.56 Bn
4	ISRG	Intuitive Surgical Inc	146.79 Bn	46.79	13.30	-
5	MDT	Medtronic plc	114.54 Bn	21.89	3.05	28.15 Bn
6	SYK	Stryker Corp	105.67 Bn	28.33	4.09	14.94 Bn
7	BSX	Boston Scientific Corp	63.93 Bn	17.65	3.04	12.62 Bn
8	QGEN	Qiagen N.V.	9.76 Bn	23.88	4.65	1.64 Bn

Qiagen QGEN

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password